Abstract
The association of clopidogrel and aspirin has become the mainstay of antiplatelet therapy in coronary artery disease, especially after stent placement. Recurrence of major coronary events including stent thrombosis in patients with good compliance to antiplatelet therapy has led to the concept of biological resistance to oral antiplatelet therapy with the ultimate goal of tailoring therapy. This concept may become a reality with the recent development of accurate point of care methods to measure platelet response to oral antiplatelet therapy. However. whether tailoring therapy based on measuring platelet inhibition is clinically relevant warrants further clinical investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
